Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text

Life Sciences, Immunology, Pathology +14

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska et al. · Arthritis & Rheumatism · 2006 · 1.1K citations

Medicine, Internal Medicine, Pharmacotherapy +13

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

Jennifer H. Anolik, Jennifer Barnard, Amedeo Cappione et al. · Arthritis & Rheumatism · 2004 · 455 citations

Life Sciences, Immunology, Pathology +17